Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 41-50 of 64
Head/Neck Cancer
Personalized, cell-based antitumor immunization with MVX-ONCO-1, combining subcutaneous implantation of irradiated autologous tumor cells and encapsulated allogeneic cells engineered to release GM-CSF: a single arm Phase II trial
Personalized, cell-based antitumor immunization with MVX-ONCO-1, combining subcutaneous implantation of irradiated autologous tumor cells and encapsulated allogeneic cells engineered to release GM-CSF: a single arm Phase II trial Summary: Head and neck squamous cell cancer has the sixth highest incidence and ranks eighth in deaths worldwide. For patients with recurrent and/or metastatic disease, the prognosis […]
Nicolas Mach, MD
Geneva University Hospital
Breast Cancer
Preoperative Breast Radiotherapy: A Tool to Provide Individualized and Biologically-Based Radiation Therapy
Preoperative Breast Radiotherapy: A Tool to Provide Individualized and Biologically-Based Radiation Therapy Summary: In 1990, the NIH concluded that conservative surgery followed by radiotherapy was the preferred treatment for women with early-stage breast cancer as no survival advantage was seen in women only receiving a more radical mastectomy. Unfortunately, some women electing to receive breast […]
Rachel Blitzblau, MD, PhD
Duke University School of Medicine
Kidney Cancer
Combining NeoVax, A Personalized Neoantigen Vaccine, with Ipilimumab to Treat Advanced Clear Cell Renal Carcinoma
Combining NeoVax, A Personalized Neoantigen Vaccine, with Ipilimumab to Treat Advanced Clear Cell Renal Carcinoma Summary: Renal Cell carcinoma, a type of kidney cancer, is one of the ten most common cancers and the incidence is increasing. Between 20 to 30% of patients initially present with metastatic disease, which is generally incurable. While newer therapies […]
Toni Choueiri,MD
Dana-Farber Cancer Institute
Pediatric Blood Cancer
LLS Pediatric Acute Leukemia (PedAL) Master Clinical Trial
LLS Pediatric Acute Leukemia (PedAL) Master Clinical Trial Summary: Therapeutic options for relapsed AML or some subsets of ALL remain limited. However, recent large-scale discovery efforts using next generation sequencing (NGS) methods have identified recurrent mutations, cellular signaling, and cell surface antigen targets for new therapies. This is a master trial that will screen each […]
Todd Cooper, DO
Leukemia Lymphoma Society / Seattle's Children's
Pediatric Blood Cancer
A Phase I Study of Venetoclax in Combination with Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults with High-Risk Hematologic Malignancies
A Phase I Study of Venetoclax in Combination with Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults with High-Risk Hematologic Malignancies Summary: Effective treatment for children and young adults with relapsed/refractory MDS, MDS-associated AML (MDS/AML), treatment related MDS/AML, and relapsed/refractory high-risk ALL/LBL continues to be a major clinical challenge with poor long-term […]
Andrew Place, MD, PhD
Dana-Farber Cancer Institute
Pediatric Blood Cancer
PARPAML: A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy
PARPAML: A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy Summary: Currently, the survival of children diagnosed with AML sits at less than 70%. Despite 80 to 90% of patients achieving first complete remission, 30 to 40% will relapse and outcomes […]
Jennifer Kamens, MD
Stanford University
Pediatric Blood Cancer
Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD
Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD Summary: Allogeneic hematopoietic stem cell transplants (stem cell transplant from a donor) [HSCT] are an important treatment for high-risk hematologic (blood) malignancies. However, these transplants can result in graft versus host disease (GVHD) which targets the skin, liver, and GI tract. This occurs in about […]
John Levine, MD, MS
Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute
Pediatric Blood Cancer
A Phase I and Expansion Cohort Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia
A Phase I and Expansion Cohort Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia Summary: Survival rates for children with AML are greater than 60%; however, the outcome for patients with relapsed or refractory disease remains poor with less than 40% becoming long term […]
Jeffrey Rubnitz, MD, PhD
St. Jude Children's Research Hospital
Pediatric Brain Cancer
Exploiting Mutant IDH1/2-induced DNA Repair Defects in Pediatric Glioma to improve outcomes
Exploiting Mutant IDH1/2-induced DNA Repair Defects in Pediatric Glioma to improve outcomes Summary: Pediatric gliomas are the most commonly encountered tumor types in children and also contribute to the most cancer related deaths in children. There is an urgent need for high-grade gliomas which lack any meaningful standard of care. IDH1/2 gene mutations are common […]
Sabine Mueller, MD, PhD
University of California, San Francisco
Pediatric Blood Cancer
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative Summary: Total body irradiation (TBI) in hematopoietic stem cell transplant (HSCT) has been a key element […]
Hisham Abdel-Azim, MD, MS
Children's Hospital Los Angeles
